Gluten-free diet can ameliorate the symptoms of non-celiac autoimmune diseases.
Study Goal
The researchers aimed to evaluate the potential of a gluten-free diet (GFD) as a therapeutic strategy for classical non-gluten-dependent autoimmune diseases.
Results Summary
The study found that 64.7% of patients (911 out of 1408) experienced a reduction in autoimmune disease symptoms after following a GFD, with 79.5% of the included studies (66 out of 83) reporting positive outcomes. The GFD was suggested to suppress harmful intestinal events and potentially act through gut-remote organ pathways.
Population
Patients aged 9 months to 69 years with various autoimmune diseases.
Effective Dosage
Not specified
Duration
1 month to 9 years
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten-free diet (GFD) | decrease | symptoms of autoimmune diseases (ADs) | patients | 64.7% (911 out of 1408 patients) | reduction in symptoms | #1 |
gluten-free diet (GFD) | decrease | symptoms of autoimmune diseases (ADs) | selected studies | 79.5% (66 out of 83 studies) | reduction in symptoms | #2 |
gluten-free diet (GFD) | decrease | several harmful intraluminal intestinal events | - | - | can suppress | #3 |
gluten-free diet (GFD) | neutral | classical non-gluten-dependent autoimmune conditions | - | - | might represent a novel nutritional therapeutic strategy | #4 |
CONTEXT: A gluten-free diet (GFD) is the recommended treatment for gluten-dependent disease. In addition, gluten withdrawal is popular and occasionally is suggested as a treatment for other autoimmune diseases (ADs). OBJECTIVE: The current systematic review summarizes those entities and discusses the logic behind using a GFD in classical non-gluten-dependentADs. DATA SOURCES: A search for medical articles in PubMed/MEDLINE, Web of Sciences, LILACS, and Scielo published between 1960 and 2020 was conducted, using the key words for various ADs and GFDs. DATA EXXTRACTION: Eight-three articles were included in the systematic review (using PRISMA guidelines). DATA ANALYSIS: Reduction in symptoms of ADs after observance of a GFD was observed in 911 out of 1408 patients (64.7%) and in 66 out of the 83 selected studies (79.5%). The age of the patients ranged from 9 months to 69 years. The duration of the GFD varied from 1 month to 9 years. A GFD can suppress several harmful intraluminal intestinal events. Potential mechanisms and pathways for the action of GFD in the gut - remote organs' axis have been suggested. CONCLUSION: A GFD might represent a novel nutritional therapeutic strategy for classical non-gluten-dependent autoimmune conditions.